Review of Fluorine-18-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography (FDG-PET) in the Follow-Up of Medullary and Anaplastic Thyroid Carcinomas
Free accessResearch articleFirst published online October, 2005
Review of Fluorine-18-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography (FDG-PET) in the Follow-Up of Medullary and Anaplastic Thyroid Carcinomas
The goal of posttreatment follow-up for medullary and anaplastic thyroid cancer (MTC and ATC) is the early diagnosis of recurrence or metastases. However, routine follow-up protocols, including physical examination and clinically oriented investigations, are not standardized, and their sensitivity in accurately detecting recurrent or metastatic disease is often suboptimal. A valuable addition to posttreatment follow-up of oncology patients is positron emission tomography using fluorine-18-2-fluoro-2-deoxy-D-glucose (FDG-PET).
Methods
We review the role of FDG-PET imaging in the follow-up of patients previously treated for MTC and ATC.
Results:
Based on the encouraging literature data, FDG-PET appears to be useful in detecting recurrent or metastatic disease in patients with MTC and ATC, providing a higher sensitivity (66% to 100%) and specificity (79% to 90%) than conventional imaging methods. However, the PET technique is limited by less accurate spatial assignment of small lesions, especially in the lung and liver.
Conclusions
Supporting evidence indicates that FDG-PET has a significant role in the follow-up of patients with MTC and ATC.
References
1.
HedingerC., WilliamsE.D., SobinL.H.. The WHO histological classification of thyroid tumors: a commentary on the second edition.Cancer.1989; 63: 908–911.
2.
GoltzmanD., PottsJ.T.Jr, RidgwayR.C.. Calcitonin as a tumor marker: use of the radioimmunoassay for calcitonin in the postoperative evaluation of patients with medullary thyroid carcinoma.N Engl J Med.1974; 290: 1035–1039.
3.
StraussL.G., ContiP.S.. The applications of PET in clinical oncology.J Nucl Med.1991; 32: 623–650.
4.
ScottA.M.. Current status of positron emission tomography in oncology.Intern Med J.2001; 31: 27–36.
5.
GrunwaldF., KalickeT., FeineU.. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study.Eur J Nucl Med.1999; 26: 1547–1552.
6.
FrillingA., TecklenborgK., GorgesR.. Preoperative diagnostic value of [18F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma.Ann Surg.2001; 234: 804–811.
7.
PlotkinM., HautzelH., KrauseB.J.. Implication of 2-18 fluoro-2-deoxyglucose positron emission tomography in the follow-up of Hurthle cell thyroid cancer.Thyroid.2002; 12: 155–161.
8.
SimonG.H., NitzscheE.U., LaubenbergerJ.J.. PET imaging of recurrent medullary thyroid cancer.Nuklearmedizin.1996; 35: 102–104.
9.
ContiP.S., DurskiJ.M., BacqaiF.. Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomography.Thyroid.1999; 9: 797–804.
10.
Brandt-MainzK., MullerS.P., GorgesR.. The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer.Eur J Nucl Med.2000; 27: 490–496.
11.
LindholmP., MinnH., Leskinen-KallioS.. Influence of the blood glucose concentration on FDG uptake in cancer: a PET study.J Nucl Med.1993; 34: 1–6.
12.
CookG.J., MaiseyM.N., FogelmanI.. Normal variants, artefacts and interpretative pitfalls in PET with 18-fluoro-2-deoxyglucose and carbon-11 methionine.Eur J Nucl Med.1999; 26: 1363–1378.
13.
BockischA., Brandt-MainzK., GorgesR.. Diagnosis in medullary thyroid cancer with [18F]FDG-PET and improvement using a combined PET/CT scanner.Acta Med Austriaca.2003; 30: 22–25.
14.
ZimmerL.A., McCookB., MeltzerC.. Combined positron emission tomography/computed tomography imaging of recurrent thyroid cancer.Otolaryngol Head Neck Surg.2003; 128: 178–184.
15.
LoweV.J., FletcherJ.W., GobarL.. Prospective investigation of positron emission tomography in lung nodules.J Clin Oncol.1998; 16: 1075–1084.
16.
RomerW., HanauskeA.R., ZieglerS.. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose.Blood.1998; 91: 4464–4471.
17.
ZasadnyK.R., WahlR.L.. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction.Radiology.1993; 189: 847–850.
18.
KeysJ.W.Jr. SUV: standard uptake value or silly useless value?J Nucl Med.1995; 36: 1836–1839.
19.
LairmoreT.C., WellsS.A.Jr. Medullary carcinoma of the thyroid: current diagnosis and management.Semin Surg Oncol.1991; 7: 92–99.
20.
GrauerA., RaueF., GagelR.F.. Changing concepts in the management of hereditary and sporadic medullary thyroid carcinoma.Endocrinol Metab Clin North Am.1990; 19: 613–635.
21.
SteinerA.L., GoodmanA.D., PowersS.R.. Study of a kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism and Cushing's disease: multiple endocrine neoplasia, type 2.Medicine (Baltimore).1968; 47: 371–409.
22.
DralleH., DammI., ScheumannG.F.. Frequency and significance of cervicomediastinal lymph node metastases in medullary thyroid carcinoma: results of a compartment-oriented microdissection method.Henry Ford Hosp Med J.1992; 40: 264–267.
23.
PaciniF., FontanelliM., FugazzolaL.. Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis in unsuspected sporadic medullary thyroid carcinoma.J Clin Endocrinol Metab.1994; 78: 826–829.
24.
BusnardoB., GirelliM.E., SimioniN.. Nonparallel patterns of calcitonin and carcinoembryonic antigen in the follow-up of medullary thyroid carcinoma.Cancer.1984; 53: 278–285.
ReinersC.. Imaging methods for medullary thyroid cancer.Recent Results Cancer Res.1992; 125: 126–145.
27.
OhtaH., YamamotoK., EndoK.. A new imaging agent for medullary carcinoma of the thyroid.J Nucl Med.1984; 25: 323–325.
28.
KrenningE.P., KwekkeboomD.J., BakkerW.H.. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.Eur J Nucl Med.1993; 20: 716–731.
29.
BarbetJ., PeltierP., BardetS.. Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody.J Nucl Med.1998; 39: 1172–1178.
30.
EndoK., ShiomiK., KasagiK.. Imaging of medullary thyroid cancer with 131I-MIBG.Lancet.1984; 324: 233.
31.
HoefnagelC.A.. Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours.Eur J Nucl Med.1994; 21: 561–581.
32.
BehrT.M., JennerN., RadetzkyS.. Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabeled gastrin.Eur J Nucl Med.1998; 25: 424–430.
33.
BollenE.C., GoeiR., van't Hof-GrootenboerB.E.. Interobserver variability and accuracy of computed tomographic assessment of nodal status in lung cancer.Ann Thorac Surg.1994; 58: 158–162.
34.
GasparoniP., RubelloD., FerlinG.. Potential role of fluorine-18-deoxyglucose (FDG) positron emission tomography (PET) in the staging of primitive and recurrent medullary thyroid carcinoma.J Endocrinol Invest.1997; 20: 527–530.
35.
MusholtT.J., MusholtP.B., DehdashtiF.. Evaluation of fluorodeoxyglucose-positron emission tomographic scanning and its association with glucose transporter expression in medullary thyroid carcinoma and pheochromocytoma: a clinical and molecular study.Surgery.1997; 122: 1049–1061.
36.
HoegerleS., AltehoeferC., GhanemN.. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels.Eur J Nucl Med.2001; 28: 64–71.
37.
AdamsS., BaumR., RinkT.. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours.Eur J Nucl Med.1998; 25: 79–83.
38.
RoelantsV., MichelL., LonneuxM.. Usefulness of [99mTC] MIBI and [18F] fluorodeoxyglucose for imaging recurrent medullary thyroid cancer and hyperparathyroidism in MEN 2a syndrome.Acta Clin Belg.2001; 56: 373–377.
39.
DiehlM., RisseJ.H., Brandt-MainzK.. Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicenter study.Eur J Nucl Med.2001; 28: 1671–1676.
40.
SzakallS.Jr, EsikO., BajzikG.. 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma.J Nucl Med.2002; 43: 66–71.
41.
SzakallS.Jr, BajzikG., RepaI.. FDG PET scan of metastases in recurrent medullary carcinoma of the thyroid gland [in Hungarian].Orv Hetil.2002; 143: 1280–1283.
42.
de GrootJ.W., LinksT.P., JagerP.L.. Impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer.Ann Surg Oncol.2004; 11: 786–794.
43.
SchmidD.T., StoeckliS.J., BandhauerF.. Impact of positron emission tomography on the initial staging and therapy in locoregional advanced squamous cell carcinoma of the head and neck.Laryngoscope.2003; 113: 888–891.
44.
JadvarH., FischmanA.J.. Evaluation of rare tumors with [F-18]fluorodeoxyglucose positron emission tomography.Clin Positron Imaging.1999; 2: 153–158.
45.
McDougallI.R., JadvarH., SegallG.. PET scan in patients with suspected recurrent thyroid cancer. Presented at Thyroid One. Thyroid Cancer Pathogenesis, Diagnosis including PET, and Treatment. International Symposium. October 7-10, 1998, Linz, Austria.Thyroid.1998; 8: 1222. Abstract.
